The Valens Company Inc. (VLNS)

[jefra1965]

https://www.proactiveinvestors.com/companies/news/913854/the-valens-company-scales-up-and-begins-to-show-what-it-was--made-to-do--913854.html

Stifel GMP has issued a "positive" buy rating and target price of $5.75 on The Valens Company (TSX:VLNS, OTCQX:VLNCF) a day after the cannabis manufacturer announced the completion of its acquisition of Verse Cannabis.

The deal for the Canadian cannabis retailer will see Valens take ownership of all of the Verse intellectual property. Just a few weeks earlier Valens also reported that it was purchasing Citizen Stash Cannabis Corp, a Canadian premium craft cannabis company, in an all-stock transaction valued at about C$54.3 million. Both deals were cited in the analyst coverage from Stifel.

“With these two transactions, VLNS captures the Verse royalty payment, reduces execution risk and provides for greater control over brand positioning at both extreme price segments in the industry, potentially balancing margin profiles,” Stifel analysts said in their note.

https://www.proactiveinvestors.com/companies/news/959347/the-valens-company-receives-positive-buy-rating-from-stifel-following-two-acquisitions-959347.html

The Valens Company (TSX:VLNS, OTCQX:VLNCF) Inc. has announced an exclusive partnership with Epsilon Healthcare Limited, a diversified global healthcare and pharmaceuticals company, for access to Epsilon's Good Manufacturing Practices (GMP) facility in Australia for manufacturing products.

In a statement, Valens said the partnership furthers its international expansion to GMP's markets in Latin America, Europe, UK, and the Asia-Pacific regions.

Products will be distributed through Valens' Australian distribution partner, Cannvalate PTY Ltd, and to date, will be the largest quantity of products provided to Cannvalate for distribution.
https://www.proactiveinvestors.com/companies/news/959768/the-valens-company-expands-international-footprint-to-asia-pacific-region-via-exclusive-australian-partnership-959768.html